A case involving the use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation in acute myocardial infarction.
- Author:
Won Ki HONG
1
;
Go Woon KIM
;
Sung Hoa LEE
;
Woo Jin LEE
;
Duck Hyoung YOON
;
Hyoung Soo KIM
;
Sang Jin HAN
Author Information
1. Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea. medhan69@hallym.or.kr
- Publication Type:Case Report
- Keywords:
Extracorporeal membrane oxygenation;
Anticoagulant;
Hemorrhage
- MeSH:
Anticoagulants;
Extracorporeal Membrane Oxygenation;
Guanidines;
Hemorrhage;
Heparin;
Humans;
Mesylates;
Middle Aged;
Myocardial Infarction;
Oxygen;
Oxygenators;
Shock;
Shock, Cardiogenic;
Tachycardia, Ventricular
- From:Korean Journal of Medicine
2010;79(2):181-186
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
It is essential during extracorporeal membrane oxygenation (ECMO) to extend the activated clotting time (ACT) using anticoagulants to prevent blood clot formation. Traditionally, heparin has been used as an anticoagulant during ECMO. Hemorrhaging due to systemic heparinization is considered a major complication of ECMO. A 48-year-old man was admitted due to cardiogenic shock with acute myocardial infarction. ECMO was instituted because of recurrent ventricular tachycardia and refractory shock. We used nafamostat mesilate (Futhan) as an anticoagulant to reduce hemorrhagic complications. The total bypass time was 153 h. The average dose of nafamostat mesilate was 2.64+/-1.11 mg/kg/h; the average ACT was 128.68+/-21.24 seconds. Only a few units were transfused, and there was no oxygenator failure or hemorrhagic complications. Thus, nafamostat mesilate may reduce the need for transfusions and hemorrhagic complications during ECMO.
